Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1456027
This article is part of the Research Topic Alternatives to Conventional Antibiotics: Biologics, Chemical Modulators and Microbiome Manipulation View all articles

Interaction of Acinetobacter sp. RIT 592 induces the production of broad-spectrum antibiotics in Exiguobacterium sp. RIT 594

Provisionally accepted
Anutthaman Parthasarathy Anutthaman Parthasarathy 1Renata Rezende Miranda Renata Rezende Miranda 2TJ Bedore TJ Bedore 2Lizabeth M. Watts Lizabeth M. Watts 2Pavan K. Mantravadi Pavan K. Mantravadi 3Narayan H. Wong Narayan H. Wong 2Jonathan Chu Jonathan Chu 2Joseph A. Adjei Joseph A. Adjei 2Amisha P. Rana Amisha P. Rana 4Michael A. Savka Michael A. Savka 2Zackery Bulman Zackery Bulman 4Eli J. Borrego Eli J. Borrego 2André O. Hudson André O. Hudson 2*
  • 1 University of Bradford, Bradford, United Kingdom
  • 2 Rochester Institute of Technology (RIT), Rochester, New York, United States
  • 3 Agilent Technologies (United States), Santa Clara, California, United States
  • 4 University of Illinois Chicago, Chicago, Illinois, United States

The final, formatted version of the article will be published soon.

    Antimicrobial resistance (AMR) is one of the most alarming global public health challenges of the 21 st century. Over 3 million antimicrobial-resistant infections occur in the United States annually, with nearly 50,000 cases being fatal. Innovations in drug discovery methods and platforms are crucial to identify novel antibiotics to combat AMR. We present the isolation and characterization of potentially novel antibiotic lead compounds produced by two rhizosphere bacteria, Acinetobacter sp. RIT 592 and Exiguobacterium sp. RIT 594. The supernatant from RIT 592 induced RIT 594 to produce a cocktail of antimicrobial compounds active against Gram-positive and negative bacteria. The antibiotic constituents were enriched using solid-phase extraction (SPE), followed by liquid chromatography (LC) and subsequent mass spectrometry (MS) analysis of collected fractions for compound structure identification and characterization. The MS data were processed through the Global Natural Product Social Molecular Networking (GNPS) database, indicating compounds with known antimicrobial activity in the bioactive samples, including oligopeptides and their derivatives. This work emphasizes the utility of microbial community-based platforms to discover novel clinically relevant secondary metabolites. Future work includes further structural characterization and antibiotic activity evaluation of the individual compounds against pathogenic multidrug-resistant (MDR) bacteria.

    Keywords: antibiotics, AMR, MDR, Bioprospecting, GNPs, antimicrobial peptides, Exiguobacterium, Acinetobacter Font: Italic Formatted: Font: Italic Formatted: Font: Italic Formatted: Font: Italic Formatted: Font: Italic

    Received: 27 Jun 2024; Accepted: 18 Jul 2024.

    Copyright: © 2024 Parthasarathy, Rezende Miranda, Bedore, Watts, Mantravadi, Wong, Chu, Adjei, Rana, Savka, Bulman, Borrego and Hudson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: André O. Hudson, Rochester Institute of Technology (RIT), Rochester, 14623-5603, New York, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.